Puma Biotechnology (PBYI) vs. Windtree Therapeutics (WINT) Head-To-Head Contrast

Puma Biotechnology (NASDAQ: PBYI) and Windtree Therapeutics (OTCMKTS:WINT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Puma Biotechnology and Windtree Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Puma Biotechnology $26.20 million 100.56 -$291.95 million ($7.85) -8.90
Windtree Therapeutics $2.04 million 4.03 -$39.49 million ($71.80) -0.04

Windtree Therapeutics has lower revenue, but higher earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Puma Biotechnology and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Puma Biotechnology N/A -278.13% -158.52%
Windtree Therapeutics -1,205.47% N/A -345.52%

Analyst Ratings

This is a breakdown of current ratings and target prices for Puma Biotechnology and Windtree Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology 0 2 7 0 2.78
Windtree Therapeutics 0 1 0 0 2.00

Puma Biotechnology currently has a consensus price target of $103.11, suggesting a potential upside of 47.62%. Given Puma Biotechnology’s stronger consensus rating and higher possible upside, equities analysts plainly believe Puma Biotechnology is more favorable than Windtree Therapeutics.

Risk and Volatility

Puma Biotechnology has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

Insider and Institutional Ownership

96.0% of Puma Biotechnology shares are held by institutional investors. Comparatively, 0.0% of Windtree Therapeutics shares are held by institutional investors. 21.1% of Puma Biotechnology shares are held by company insiders. Comparatively, 0.8% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Puma Biotechnology beats Windtree Therapeutics on 10 of the 13 factors compared between the two stocks.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply